PINK1/PARK2-Mediated Mitophagy Enhancement for Neuroinflammation Control

Target: PINK1 Composite Score: 0.571 Price: $0.58▲1.9% Citation Quality: Pending Neuroinflammation Status: promoted Variant of NLRP3/Mitophagy Coupling Modulation
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
🔮 Lysosomal / Autophagy 🔬 Microglial Biology 🧠 Neurodegeneration 🔥 Neuroinflammation 🟢 Parkinson's Disease 🟡 ALS / Motor Neuron Disease
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
15
Citations
1
Debates
13
Supporting
2
Opposing
Quality Report Card click to collapse
C+
Composite: 0.571
Top 52% of 1875 hypotheses
T2 Supported
Literature-backed with debate validation
Needs convergence ≥0.40 (current: 0.00) for Established
A Mech. Plausibility 15% 0.85 Top 9%
C Evidence Strength 15% 0.41 Top 78%
F Novelty 12% 0.00 Top 50%
F Feasibility 12% 0.00 Top 50%
F Impact 12% 0.00 Top 50%
A+ Druggability 10% 0.90 Top 17%
A Safety Profile 8% 0.80 Top 17%
A Competition 6% 0.85 Top 19%
B+ Data Availability 5% 0.75 Top 26%
A Reproducibility 5% 0.80 Top 14%
Evidence
13 supporting | 2 opposing
Citation quality: 85%
Debates
1 session A
Avg quality: 0.85
Convergence
0.00 F 6 related hypothesis share this target

From Analysis:

Immune atlas neuroinflammation analysis in neurodegeneration

Comprehensive analysis of immune cell subtypes in neurodegeneration: microglia subtypes (DAM, homeostatic, inflammatory), astrocyte reactivity states, T-cell infiltration. Anchor to existing TREM2 (h-b234254c, h-044ee057) and complement cascade hypotheses (h-58e4635a, h-1fe4ba9b, h-5a55aabc). Produce inflammatory pathway diagrams and generate 3-5 new hypotheses connecting immune findings to disease mechanisms.

→ View full analysis & debate transcript

Description

Molecular Mechanism and Rationale

The PINK1/PARK2 mitophagy pathway represents a critical quality control mechanism that maintains mitochondrial homeostasis through selective autophagy of damaged organelles. Under normal conditions, PINK1 (PTEN-induced kinase 1) is constitutively imported into healthy mitochondria via the TOM/TIM complex, where it undergoes proteolytic cleavage by the mitochondrial processing peptidase (MPP) and presenilin-associated rhomboid-like (PARL) protease, leading to rapid degradation. However, when mitochondrial membrane potential (Δψm) decreases below a critical threshold due to oxidative stress, inflammatory cytokines, or metabolic dysfunction, PINK1 import is blocked, causing stabilization and accumulation on the outer mitochondrial membrane (OMM).

...

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["DAMPs / PAMPs Detection"] --> B["NLRP3 Inflammasome Assembly"]
    B --> C["Caspase-1 Activation"]
    C --> D["GSDMD Cleavage"]
    D --> E["Membrane Pore Formation"]
    E --> F["IL-1β / IL-18 Release"]
    F --> G["Pyroptotic Cell Death"]
    H["NLRP3 Intervention"] --> I["Inflammasome Inhibition"]
    I --> J["Blocked Pyroptosis"]
    J --> K["Reduced Neuroinflammation"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style H fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style K fill:#1b5e20,stroke:#81c784,color:#81c784

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for PINK1 from GTEx v10.

Frontal Cortex BA969.6 Cortex62.1 Spinal cord cervical c-154.3 Anterior cingulate cortex BA2454.1 Substantia nigra50.5 Nucleus accumbens basal ganglia46.4 Amygdala46.2 Putamen basal ganglia40.0 Caudate basal ganglia39.8 Hypothalamus39.0 Cerebellar Hemisphere37.1 Cerebellum35.8 Hippocampus33.4median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.85 (15%) Evidence 0.41 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.90 (10%) Safety 0.80 (8%) Competition 0.85 (6%) Data Avail. 0.75 (5%) Reproducible 0.80 (5%) KG Connect 0.94 (8%) 0.571 composite
15 citations 13 with PMID Validation: 85% 13 supporting / 2 opposing
For (13)
No supporting evidence
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
11
2
2
MECH 11CLIN 2GENE 2EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Parkin regulates microglial NLRP3 and represses ne…SupportingMECH----PMID:37029500-
Quercetin alleviates neurotoxicity via NLRP3 infla…SupportingMECH----PMID:34082381-
NLRP3 inflammasome activation drives tau pathologySupportingMECH----PMID:31748742-
NLRP3 inflammasome has important beneficial roles …OpposingMECH------
Excessive mitophagy enhancement could deplete func…OpposingMECH------
Human Monocytes Engage an Alternative Inflammasome…SupportingMECHImmunity MODERATE2016-PMID:27037191-
P2X7R Modulates NEK7-NLRP3 Interaction to Exacerba…SupportingMECHInt J Biol Sci MODERATE2024-PMID:38993566-
Akkermansia muciniphila Alleviates Dextran Sulfate…SupportingMECHMicrobiol Spect… MODERATE2021-PMID:34612661-
HSP90β controls NLRP3 autoactivationSupportingMECHSci Adv MODERATE2024-PMID:38416826-
The expanding role of the NLRP3 inflammasome from …SupportingCLINNat Immunol MODERATE2025-PMID:40826276-
NLRP3 is activated in Alzheimer's disease and…SupportingGENENature MODERATE2013-PMID:23254930-
The NLRP3 inflammasome: contributions to inflammat…SupportingGENECell Mol Biol L… MODERATE2023-PMID:37370025-
Microglia and Alzheimer's DiseaseSupportingCLINInt J Mol Sci MODERATE2022-PMID:36361780-
NLRP3 inflammasome signalling in Alzheimer's …SupportingMECHNeuropharmacolo… MODERATE2024-PMID:38565393-
H4K12 lactylation-regulated NLRP3 is involved in c…SupportingMECHJ Hazard Mater MODERATE2025-PMID:39862777-
Legacy Card View — expandable citation cards

Supporting Evidence 13

Parkin regulates microglial NLRP3 and represses neurodegeneration in PD
Quercetin alleviates neurotoxicity via NLRP3 inflammasome and mitophagy interplay
NLRP3 inflammasome activation drives tau pathology
Human Monocytes Engage an Alternative Inflammasome Pathway MODERATE
Immunity · 2016 · PMID:27037191
P2X7R Modulates NEK7-NLRP3 Interaction to Exacerbate Experimental Autoimmune Prostatitis via GSDMD-mediated Pr… MODERATE
P2X7R Modulates NEK7-NLRP3 Interaction to Exacerbate Experimental Autoimmune Prostatitis via GSDMD-mediated Prostate Epithelial Cell Pyroptosis
Int J Biol Sci · 2024 · PMID:38993566
Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by NLRP3 Activation MODERATE
Microbiol Spectr · 2021 · PMID:34612661
HSP90β controls NLRP3 autoactivation MODERATE
Sci Adv · 2024 · PMID:38416826
The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets MODERATE
Nat Immunol · 2025 · PMID:40826276
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice MODERATE
Nature · 2013 · PMID:23254930
The NLRP3 inflammasome: contributions to inflammation-related diseases MODERATE
Cell Mol Biol Lett · 2023 · PMID:37370025
Microglia and Alzheimer's Disease MODERATE
Int J Mol Sci · 2022 · PMID:36361780
NLRP3 inflammasome signalling in Alzheimer's disease MODERATE
Neuropharmacology · 2024 · PMID:38565393
H4K12 lactylation-regulated NLRP3 is involved in cigarette smoke-accelerated Alzheimer-like pathology through … MODERATE
H4K12 lactylation-regulated NLRP3 is involved in cigarette smoke-accelerated Alzheimer-like pathology through mTOR-regulated autophagy and activation of microglia
J Hazard Mater · 2025 · PMID:39862777

Opposing Evidence 2

NLRP3 inflammasome has important beneficial roles in pathogen defense and cellular stress responses
Excessive mitophagy enhancement could deplete functional mitochondria
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-03 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Based on my comprehensive analysis of neuroinflammation in neurodegeneration, I'll now generate 7 novel therapeutic hypotheses connecting immune findings to disease mechanisms. These hypotheses build upon the existing TREM2 and complement cascade research while proposing new mechanistic pathways.

Novel Therapeutic Hypotheses for Neuroinflammation in Neurodegeneration

Hypothesis 1: Galectin-3/TREM2 Competitive Inhibition Therapy

Title: Selective Galectin-3 antagonism enhances beneficial TREM2 signaling in disease-associated microglia

Description: Galectin-3 acts as an endogeno

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Neuroinflammation Therapeutic Hypotheses

Hypothesis 1: Galectin-3/TREM2 Competitive Inhibition Therapy

Revised Confidence: 0.45 (↓ from 0.78)

Critical Weaknesses:

  • The PMIDs cited appear fabricated (40543907, 40074166) - these are future dates and don't exist in PubMed
  • Limited evidence for direct galectin-3/TREM2 competition at the molecular level
  • Galectin-3 has diverse roles beyond TREM2 interaction, making selective targeting challenging
  • No consideration of galectin-3's beneficial roles in tissue repair and wound healing

**Alternative Explanati

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Drug Development Feasibility Assessment: Neuroinflammation Therapeutic Hypotheses

Based on my comprehensive analysis of the proposed hypotheses and current therapeutic landscape, I'll assess each hypothesis for practical drug development feasibility.

HYPOTHESIS 1: Galectin-3/TREM2 Competitive Inhibition Therapy

Revised Feasibility Score: 6/10 (Moderate)

Druggability Assessment

  • Target: Galectin-3 (LGALS3) - HIGHLY DRUGGABLE
  • Chemical Matter: Multiple validated scaffolds exist
  • Existing Compounds:
  • Belapectin (GR-MD-02) - Completed Phase 2b in NASH (NC

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.560.580.59 0.60 0.55 2026-04-202026-04-222026-04-28 Market PriceScoreevidencedebate 9 events
7d Trend
Stable
7d Momentum
▲ 2.1%
Volatility
Low
0.0070
Events (7d)
5

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (13)

No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
Microglia and Alzheimer's Disease.
Int J Mol Sci (2022) · PMID:36361780
No extracted figures yet
No extracted figures yet
No extracted figures yet
HSP90β controls NLRP3 autoactivation.
Sci Adv (2024) · PMID:38416826
No extracted figures yet
NLRP3 inflammasome signalling in Alzheimer's disease.
Neuropharmacology (2024) · PMID:38565393
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

Origin

mutate · gen 1
parent: h-f10d82a7
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score
0.18
9.3th percentile (776 hypotheses)
Tokens Used
9,488
KG Edges Generated
4,920
Citations Produced
15

Cost Ratios

Cost per KG Edge
9488.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
632.53 tokens
Lower is better (baseline: 1000)
Cost per Score Point
17003.58 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.018
10% weight of efficiency score
Adjusted Composite
0.589

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for PINK1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for PINK1 →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (18)

APOE4C1QAC3GALECTIN3GZMBLDHAMFN2NFKB1NLRP3PPARGC1APRF1SPP1TREM2h-immunity-03dc171eh-immunity-50f8d4f4h-immunity-6e54942bh-immunity-c3bc272fh-immunity-c64967ab

Related Hypotheses

Dose-Response Framework: PINK1/Parkin Mitophagy as the Critical Mediator Linking HBOT Parameters to Tau Clearance
Score: 0.614 | neurodegeneration
Mitophagy collapse via PINK1-PRKN is the primary autophagy lesion after irradiation
Score: 0.614 | neurodegeneration
PINK1/PARK2-LC3 Mitophagy Enhancement
Score: 0.485 | Neuroinflammation
PINK1/PARK2 Mitophagy Enhancement for Microglial Polarization
Score: 0.380 | Neuroinflammation
Mitophagy Enhancement Blocks STING-Mediated Neuroinflammation in ALS
Score: 0.380 | Neuroinflammation

Estimated Development

Estimated Cost
$0
Timeline
5.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified
IF PINK1 is pharmacologically activated (via 1 µmol/kg kinetin, twice daily for 28 days) in 8-week-old 5xFAD mice, THEN hippocampal IL-1β protein levels will decrease by ≥30% and Iba1+ microglial density will decrease by ≥25% compared to vehicle-treated 5xFAD controls within 6 weeks.
pending conf: 0.72
Expected outcome: 30-40% reduction in IL-1β (target: <15 pg/mg protein vs. ~22 pg/mg in controls) and 25-35% reduction in microglial activation markers.
Falsified by: IL-1β levels remain within 10% of vehicle control OR increase; microglial density unchanged or increased; pSer65-Ub signal unchanged by Western blot.
Method: C57BL/6J 5xFAD mice (n≥12/group) treated with kinetin or vehicle via oral gavage; endpoint: stereological Iba1+ cell count, Meso Scale Discovery IL-1β/TNF-α assay of hippocampal homogenates, pSer65-Ub Western blot.
IF PINK1 is genetically knocked down (shRNA targeting exon 2, AAV9 delivery to substantia nigra) in MPTP-induced parkinsonian mice, THEN NLRP3 inflammasome activation (caspase-1 activity) will increase by ≥50% and mitochondrial ROS will increase by ≥40% compared to AAV9-empty vector controls within 5 weeks.
pending conf: 0.68
Expected outcome: 50-70% increase in caspase-1 fluorometric activity and 40-60% increase in MitoSox fluorescence intensity indicating exacerbation of neuroinflammation.
Falsified by: Caspase-1 activity within 15% of control; ROS unchanged or decreased; PINK1 knockdown confirmed but no measurable effect on inflammasome readout.
Method: C57BL/6J mice (n≥10/group) receiving AAV9-shPINK1 or AAV9-empty into SNpc, followed by MPTP (20 mg/kg i.p., 5 days), with endpoint: caspase-1 activity assay, MitoSox flow cytometry, striatal TH+ neuron count.

Knowledge Subgraph (13 edges)

co discussed (1)

MFN2NLRP3

relates to (12)

h-immunity-c64967abTREM2h-immunity-c64967abAPOE4h-immunity-c64967abLDHAh-immunity-c3bc272fTREM2h-immunity-c3bc272fC1QA
▸ Show 7 more

Mechanism Pathway for PINK1

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    MFN2["MFN2"] -->|co discussed| NLRP3["NLRP3"]
    h_immunity_c64967ab["h-immunity-c64967ab"] -->|relates to| TREM2["TREM2"]
    h_immunity_c64967ab_1["h-immunity-c64967ab"] -->|relates to| APOE4["APOE4"]
    h_immunity_c64967ab_2["h-immunity-c64967ab"] -->|relates to| LDHA["LDHA"]
    h_immunity_c3bc272f["h-immunity-c3bc272f"] -->|relates to| TREM2_3["TREM2"]
    h_immunity_c3bc272f_4["h-immunity-c3bc272f"] -->|relates to| C1QA["C1QA"]
    h_immunity_6e54942b["h-immunity-6e54942b"] -->|relates to| C3["C3"]
    h_immunity_6e54942b_5["h-immunity-6e54942b"] -->|relates to| NFKB1["NFKB1"]
    h_immunity_6e54942b_6["h-immunity-6e54942b"] -->|relates to| PPARGC1A["PPARGC1A"]
    h_immunity_50f8d4f4["h-immunity-50f8d4f4"] -->|relates to| GZMB["GZMB"]
    h_immunity_50f8d4f4_7["h-immunity-50f8d4f4"] -->|relates to| PRF1["PRF1"]
    h_immunity_03dc171e["h-immunity-03dc171e"] -->|relates to| SPP1["SPP1"]
    style MFN2 fill:#ce93d8,stroke:#333,color:#000
    style NLRP3 fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_c64967ab fill:#4fc3f7,stroke:#333,color:#000
    style TREM2 fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_c64967ab_1 fill:#4fc3f7,stroke:#333,color:#000
    style APOE4 fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_c64967ab_2 fill:#4fc3f7,stroke:#333,color:#000
    style LDHA fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_c3bc272f fill:#4fc3f7,stroke:#333,color:#000
    style TREM2_3 fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_c3bc272f_4 fill:#4fc3f7,stroke:#333,color:#000
    style C1QA fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_6e54942b fill:#4fc3f7,stroke:#333,color:#000
    style C3 fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_6e54942b_5 fill:#4fc3f7,stroke:#333,color:#000
    style NFKB1 fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_6e54942b_6 fill:#4fc3f7,stroke:#333,color:#000
    style PPARGC1A fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_50f8d4f4 fill:#4fc3f7,stroke:#333,color:#000
    style GZMB fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_50f8d4f4_7 fill:#4fc3f7,stroke:#333,color:#000
    style PRF1 fill:#ce93d8,stroke:#333,color:#000
    style h_immunity_03dc171e fill:#4fc3f7,stroke:#333,color:#000
    style SPP1 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 PINK1 — PDB 6EQI Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Immune atlas neuroinflammation analysis in neurodegeneration

Neuroinflammation | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Edit History

Action Actor Timestamp Reason Changes
update codex:51 2026-04-26T14:44 Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d Changes recorded
update codex:51 2026-04-26T14:44 Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d Changes recorded

View full edit history (JSON)

Same Analysis (5)

NLRP3/Mitophagy Coupling Modulation
Score: 0.68 · NLRP3
PINK1/PARK2-LC3 Mitophagy Enhancement
Score: 0.48 · PINK1
TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome
Score: 0.48 · TFEB
PINK1/PARK2 Mitophagy Enhancement for Microglial Polarization
Score: 0.38 · PINK1
STING-Mediated NLRP3 Inflammasome Priming in ALS Microglia
Score: 0.38 · TMEM173
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.